EvoEndo

About EvoEndo

EvoEndo, Inc. is a medical device company founded in 2017 that is focused on shifting the paradigm of gastrointestinal endoscopy. The firm has developed a system to perform transnasal esophagogastroduodenoscopy (TNE) without the need for sedation or general anesthesia, targeting both pediatric and adult patients. The company was co-founded by Dr. Joel Friedlander, a pediatric gastroenterologist at Children's Hospital Colorado. Dr. Friedlander's experience in treating children with complex airway, respiratory, and gastrointestinal disorders, and his observation of the smaller, less invasive scopes used by his pulmonology colleagues, inspired the development of a pediatric-focused transnasal endoscope. He aimed to create a less burdensome method for diagnosing and monitoring conditions like GERD, eosinophilic esophagitis (EoE), and celiac disease, which often require repeated procedures.

The company's core offering is the EvoEndo Single-Use Endoscopy System, which received its initial FDA 510(k) clearance in February 2022 for patients five years and older. This clearance was expanded in July 2025 to include patients of all ages, from neonates to adults. The system features a sterile, single-use, ultra-slim flexible gastroscope with a portable controller. A key element of the patient experience is a virtual reality component for distraction during the procedure, reducing patient apprehension. This approach allows for procedures to be conducted in a clinical setting rather than an operating room, presenting a significant cost and time-saving advantage. The single-use nature of the scope eliminates capital costs for cleaning and repair and mitigates the risk of cross-contamination associated with reusable devices. Revenue is generated from the sale of the disposable endoscopes and associated equipment to hospitals and ambulatory surgery centers (ASCs). The company has established a distribution agreement with Micro-Tech Endoscopy USA to commercialize the system.

Operationally, EvoEndo is headquartered in Colorado and has secured significant funding to support its commercial launch and clinical studies, raising over $30 million through various financing rounds, including a Series A. The leadership team has evolved, with Jonathan Hartmann taking over as CEO in April 2023, bringing extensive experience from leadership roles at companies like Sofregen Medical and Boston Scientific's endoscopy division. Heather Underwood, the former CEO who led the company through its critical FDA clearance and initial commercialization phases, has a background in medical device entrepreneurship and the Stanford Biodesign program. The company's market strategy initially targets the pediatric diagnostic upper GI procedure market, with plans to expand into the much larger adult market, where over 7 million upper endoscopies are performed annually in the U.S.